Anzeige
Mehr »
Login
Dienstag, 22.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
Endlich!!! Gold-Aktien explodieren! Jetzt die Chance auf riesige Gewinne nutzen – mit dieser Aktie!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
605 Leser
Artikel bewerten:
(2)

ForFarmers N.V.: Yoram Knoop (CEO) to step down after Annual General Meeting in 2022

Lochem, 25 November 2021

Yoram Knoop (CEO) to step down after Annual General Meeting in 2022

ForFarmers announces that Yoram Knoop, CEO and member of the Executive Board of ForFarmers N.V. will step down after the Annual General Meeting of Shareholders on 14 April 2022, the date on which his current term ends. This has been decided in mutual consultation between Yoram Knoop and the Supervisory Board.

"After having led this great company for eight years, it is a natural moment for a new phase for myself and the company. I am proud of ForFarmers and of what we have achieved with our mission For the Future of Farming especially for customers, as well as of the constructive cooperation with colleagues. During the coming months, I will continue to work on the execution of our management agenda with all my energy and dedication", Yoram Knoop states.

Yoram Knoop joined ForFarmers in November 2013 and became CEO of ForFarmers as of 1 January 2014. He will remain operational as CEO until the end of the Annual Meeting of Shareholders in 2022.

Jan van Nieuwenhuizen, chairman of the Supervisory Board of ForFarmers: "Although Yoram is still in position as CEO until 14 April coming, a word of thanks is currently very much in order given his enormous dedication to ForFarmers and its stakeholders. Since he was first appointed, Yoram has further developed the company from an ambitious cooperative to the leading feed company in Europe. Under his leadership, ForFarmers made the step into the growth market Poland and more balance was brought to the portfolio by enhancing the position in the poultry sector. In addition, Yoram embedded sustainability in ForFarmers' strategy."

The process of finding a new CEO has started.
In light of the changes and challenges in the agricultural sector, ForFarmers will evaluate and where appropriate tighten up its strategy Build to Grow 2025.

This press release contains information that qualifies as inside information in the sense of Article 7 paragraph 1 of the EU Market Abuse Regulation.


Note to the editor / For additional information:

Caroline Vogelzang, Director Investor Relations
T: 0031 573 288 000 M: 0031 6 10 94 91 61
E: caroline.vogelzang@forfarmers.eu

About ForFarmers N.V.
ForFarmers N.V. is an international organisation that provides complete innovative feed solutions to the livestock farming industry. With its 'For the Future of Farming' mission ForFarmers is committed to the continuity of farming and to further increasing the sustainability of the agricultural sector.


ForFarmers is the market leader in Europe with annual sales of around 10 million tonnes of animal feed. The company is active in the Netherlands, Belgium, Germany, Poland and the United Kingdom. ForFarmers has approximately 2,500 employees. In 2020 revenue amounted to approximately €2.4 billion. ForFarmers N.V. is listed on Euronext Amsterdam.
ForFarmers N.V. is listed on Euronext Amsterdam.

ForFarmers N.V., P.O. Box 91, 7240 AB Lochem, T: +31, www.forfarmersgroup.eu

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, including those relating to ForFarmers legal obligations in terms of capital and liquidity positions in certain specified scenarios. In addition, forward-looking statements, without limitation, may include such phrases as "intends to", "expects", "takes into account", "is aimed at ", 'plans to", "estimated" and words with a similar meaning. These statements pertain to or may affect matters in the future, such as ForFarmers future financial results, business plans and current strategies. Forward-looking statements are subject to a number of risks and uncertainties, which may mean that there could be material differences between actual results and performance and expected future results or performances that are implicitly or explicitly included in the forward-looking statements. Factors that may result in variations on the current expectations or may contribute to the same include but are not limited to: developments in legislation, technology, jurisprudence and regulations, share price fluctuations, legal procedures, investigations by regulatory bodies, the competitive landscape and general economic conditions. These and other factors, risks and uncertainties that may affect any forward-looking statements or the actual results of ForFarmers, are discussed in the last published annual report. The forward-looking statements in this press release are only statements as of the date of this document and ForFarmers accepts no obligation or responsibility with respect to any changes made to the forward-looking statements contained in this document, regardless of whether these pertain to new information, future events or otherwise, unless ForFarmers is legally obliged to do so.


© 2021 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.